Abstract
In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.
Original language | English |
---|---|
Pages (from-to) | 378-385 |
Number of pages | 8 |
Journal | Annals of Oncology |
Volume | 26 |
Issue number | 2 |
DOIs | |
Publication status | Published - 1 Feb 2015 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Oncology
Keywords
- Kidney cancer
- Mammalian target of rapamycin (mTOR)
- Sequence
- Tyrosine kinase inhibitor